share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ambrose Kristen

SEC announcement ·  Apr 3 16:04
Summary by Moomoo AI
Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two consecutive days. On April 1, 2024, Ambrose sold 225 shares at a price of $418.1 per share, followed by the sale of 240 shares at $419.0 per share on April 2, 2024. The transactions resulted in a total disposal of 465 shares, with the total market value of the disposed shares amounting to $194,632.5. After these transactions, Ambrose's direct holdings in Vertex Pharmaceuticals totaled 7,500 shares. The sales were executed as part of standard financial management, with the first sale being a payment of exercise price or tax liability by delivering or withholding securities, and the second being an open market or private sale.
Kristen Ambrose, SVP & Chief Accounting Officer of Vertex Pharmaceuticals Inc. (VRTX), completed the sale of company shares on two consecutive days. On April 1, 2024, Ambrose sold 225 shares at a price of $418.1 per share, followed by the sale of 240 shares at $419.0 per share on April 2, 2024. The transactions resulted in a total disposal of 465 shares, with the total market value of the disposed shares amounting to $194,632.5. After these transactions, Ambrose's direct holdings in Vertex Pharmaceuticals totaled 7,500 shares. The sales were executed as part of standard financial management, with the first sale being a payment of exercise price or tax liability by delivering or withholding securities, and the second being an open market or private sale.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more